Abstract
In 2018, the ARRIVE trial (Grobman et al. N Engl J Med. 2018) reported that 39-week elective labor induction in nulliparas decreased cesarean birth and pre-eclampsia rates compared with expectant management. Our hypothesis was that this publication had an immediate impact on induction practices and decreased cesarean birth and preeclampsia rates over time.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
